Resource Logo
NLM AIDSLINE

HIV viral load changes in Delta patients.




 

3rd Conf Retro and Opportun Infect. 1996 Jan 28-Feb 1;:162. Unique

A subset of 230 Delta1 -AZT naive-patients were recruited in 22 selected centers in France, UK and Netherlands for virological studies including viral load quantitation. Quantitative cellular and plasma viremia were performed by a consensus methodology at week -2, 0, 4, 12, 24, 48, 64 and 96. Plasma RNA measurement was assayed by the Monitor Roche Molecular Systems assay on specimens collected twice at baseline, monthly up to W16, every two months until W64, then every four months. Of the 230 patients, 85 had been randomised to Zidovudine (AZT) monotherapy, 73 to AZT + didanosine (ddl) and 72 to AZT + Zalcitabine(ddC). At baseline, the virology subset patients had a mean and a median CD4 cell count of 210 [IQR: 123-280]; 52% were asymptomatic, 31% had ARC and 17% AIDS. Quantitative cellular and plasma viremia were positive in 91% and 61.6% of the patients respectively. Changes in quantitative cultures and RNA viral load will be reported.

Antiviral Agents/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE CD4 Lymphocyte Count Didanosine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Drug Therapy, Combination HIV Infections/BLOOD/*DRUG THERAPY HIV-1/GENETICS/*ISOLATION & PURIF Human RNA, Viral/BLOOD Zalcitabine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Zidovudine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE ABSTRACT



 




Information in this article was accurate in November 30, 1996. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.